Form 8-K - Current report:
SEC Accession No. 0001213900-25-061471
Filing Date
2025-07-03
Accepted
2025-07-03 16:01:34
Documents
13
Period of Report
2025-07-03
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248135-8k_jasper.htm   iXBRL 8-K 47328
  Complete submission text file 0001213900-25-061471.txt   255972

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE jspr-20250703.xsd EX-101.SCH 3759
3 XBRL DEFINITION FILE jspr-20250703_def.xml EX-101.DEF 26605
4 XBRL LABEL FILE jspr-20250703_lab.xml EX-101.LAB 36660
5 XBRL PRESENTATION FILE jspr-20250703_pre.xml EX-101.PRE 25229
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248135-8k_jasper_htm.xml XML 5641
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 251105498
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)